Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bem4.3
Bempedoic Acid – Forschung
Überwiegend Mechanismus / Beobachtung
43 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Bempedoic Acid sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2016–2026 mit einer typischen Studiengröße von 970 Teilnehmenden.
Basierend auf 43 Studien · 3 Meta-Analysen · 9 RCTs · 145,962 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
LDL cholesterol & lipidsSenkt LDL-C ~15-25% als Monotherapie; CLEAR Outcomes zeigte eine signifikante Reduktion schwerwiegender kardiovaskulärer Ereignisse bei statin-intoleranten Patienten · Wochen (Ereignisse: Monate bis Jahre)
Überwiegend Mechanismus / Beobachtung36 Studien
Cardiovascular eventsSenkt LDL-C ~15-25% als Monotherapie; CLEAR Outcomes zeigte eine signifikante Reduktion schwerwiegender kardiovaskulärer Ereignisse bei statin-intoleranten Patienten · Wochen (Ereignisse: Monate bis Jahre)
Überwiegend Mechanismus / Beobachtung24 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung16 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung8 Studien
Liver health
Zu wenige bewertete Studien2 Studien
Aktives Forschungsgebiet
37 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201620212026
1Meta-Analysen=1,313 · large study2026
Our study contributes to a nuanced understanding of the biochemical effects of lipid-lowering therapies, potentially guiding future clinical practices and research in cardiovascular risk management.
Meng L, Huang T, Guo S, Wang T, Xu R, Wang X, Li L, Yang Y, Yang R, Wang J, Yang H, Ma Y, Yang B, Luo J, Jiao L. · Diabetes, obesity & metabolism (2026)
Results indicate a significant increase in plasma PCSK9 levels following treatment with conventional lipid-lowering drugs (weighted mean difference: 23.25 ng/mL; 95% confidence interval: 17.00, 29.50; p < 0.01; I 2 = 56%).
Notably, subgroup analyses reveal significant differences based on treatment intensity, type of lipid-lowering agent, underlying diseases, and trial location.
This systematic review confirms that conventional lipid-lowering drugs significantly elevate plasma PCSK9 levels.
Conclusion: Bempedoic acid is a safe and effective alternative to statins in high-risk patients intolerant to statins, decreasing the risk of MACE.
Hamayal M, Shahid W, Akhtar CH, Shekiba F, Iftikhar I, Tahir MD, Awwab M, Hussain S, Naeem S, Hafeez M. · Future cardiology (2024)
Treatment with bempedoic acid was associated with a reduced risk of MACE compared with placebo (RR 0.86; 95% CI [0.79, 0.94] p = 0.0005), with myocardial infarction significantly reduced.
Incidence of adverse effects was increased with bempedoic acid (RR: 1.02; 95% [1.00, 1.03] p = 0.01) but no significant difference was observed.
Incidence of myalgia was reduced in bempedoic group as well.
The studies presented at ACC 2026 emphasize the importance of intensive lipid-lowering strategies, expand the use of new cardiometabolic therapies, and showcase emerging diagnostic and preventive strategies for ASCVD.
Abdul Jabbar AB et al. · Current atherosclerosis reports (2026)
By helping to reduce residual cardiovascular risk and bridge treatment gaps in patients who may not be eligible for or have access to PCSK9 inhibitors, bempedoic acid represents a valuable addition to personalised lipid management strategies aimed at lowering cardiovascular morbidity and mortality in this high-risk population.
Federici M, Buzzetti R, Candido R, De Cosmo S, Pirillo A, Russo G, Sesti G, Avogaro A. · Cardiovascular diabetology (2026)
Importantly, the CLEAR Outcomes trial showed a significant reduction in major adverse cardiovascular events in statin-intolerant patients, almost half of whom had diabetes, without adverse effects on glycaemic control.
Prospective studies are warranted to confirm these findings.
Rhabneh L, Ababneh R, Alnaser I, Aloqaily M, Alfarrajin I, Albadawi I, Amawi A. · Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego (2026)
MACE occurred more frequently in the atorvastatin group (5.7%) compared to the combination therapy group (3.2%), with a hazard ratio of 1.606 (95% CI: 1.302-1.980, P<0.001).
Cardiac arrest and all-cause hospitalizations were also higher in the atorvastatin group, with hazard ratios of 1.628 (95% CI: 1.041-2.544, P<0.001) and 1.418 (95% CI: 1.177-1.710, P<0.001), respectively.
No significant difference in myopathy was observed (HR 0.915, 95% CI: 0.741-1.129).
In this review, we aimed at summarizing the evidences on lipid metabolism alterations in cancer cells, the effects of various antineoplastic drugs on lipid metabolism, and the potential role of lipid-lowering therapies in patients with cancer, with a particular focus on more recently introduced agents such as PCSK9 inhibitors and bempedoic acid.
Bisceglia I et al. · Giornale italiano di cardiologia (2006) (2026)
Cholesterol is an essential component of cellular membranes and a precursor of biologically active molecules that are fundamental in maintaining organism homeostasis.
Interest on the role of cholesterol and lipid-lowering agents in cancer patients has progressively grown, following the evidence that cholesterol metabolism is altered in tumor cells.
Intracellular cholesterol levels clearly influence oncogenic signaling pathways, while lipid-lowering drugs offer cardioprotective effects for individuals undergoing potentially cardiotoxic therapies.
Transitioning from an LDL cholesterol-centric to an apoB-centric framework may represent a biologically integrated strategy to reduce both atherosclerotic cardiovascular disease and triglyceride-mediated pancreatitis risk.
Gaudet D et al. · Circulation research (2026)
Emerging therapeutic strategies targeting the angiopoietin-like protein axis, apo CIII, Lp(a), CETP (cholesteryl ester transfer protein), hepatic lipid flux, and incretin signaling expand the therapeutic landscape for modulating apoB-containing lipoproteins.
Gene-targeted approaches, including gene editing, epigenome editing, small interfering RNA, and antisense oligonucleotides, as well as novel oral or injectable agents and combination therapies, further broaden opportunities for durable apoB modulation.
Transitioning from an LDL cholesterol-centric to an apoB-centric framework may represent a biologically integrated strategy to reduce both atherosclerotic cardiovascular disease and triglyceride-mediated pancreatitis risk.
Future research should focus on refining risk stratification, improving lipid target attainment, and integrating novel lipid-modifying agents to enhance cardiovascular outcomes in this high-risk population.
Brandts J et al. · Cardiovascular diabetology (2026)
Triglyceride-lowering therapies, including omega-3 fatty acids and fibrates, have demonstrated substantial reductions in triglyceride levels, but their impact on cardiovascular outcomes remains uncertain.
Given the heterogeneity of dyslipidemia in diabetes, non-HDL-C and apolipoprotein B (apoB) have emerged as superior markers for assessing atherogenic burden.
While LDL-C reduction remains central, additional efforts are needed to optimise the management of residual atherogenic lipoprotein particles in diabetes.
This review consolidates current knowledge on ACLY in kidney diseases, highlighting its mechanistic contributions, and underscoring its significant potential for diagnostic and therapeutic innovation.
Wei M et al. · Renal failure (2026)
Furthermore, ACLY activity influences hypocitraturia, a key factor in nephrolithiasis, and is upregulated in polycystic kidney disease, where its inhibition attenuates cystic growth.
Given its central role across diverse renal pathologies, ACLY emerges as a promising therapeutic target.
Several inhibitors, including bempedoic acid, SB-204990, and natural compounds, show potential in modulating ACLY activity.
Conclusions Thus, the iatrogenic increase of plasma uric acid levels by the inhibition of OAT does not appear to have a clinically relevant negative impact on cardiovascular diseases.
Bonanni L, Biolo M, Marodin G, Portinari C, Simioni P, Ferri N. · Nutrition, metabolism, and cardiovascular diseases : NMCD (2026)
Data synthesis The increased levels of uric acid were associated with higher incidence of gout and could potentially have a negative effect on cardiovascular diseases.
Finally, uric acid lowering agents have not consistently demonstrated cardiovascular benefit in randomized clinical trials, and other drugs increasing, to the same extent, uric acid plasma levels, i.e. thiazide diuretic, do not increase cardiovascular risk.
The present article presents the treatment recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in people with diabetes according to current scientific evidence.
Wascher TC et al. · Wiener klinische Wochenschrift (2026)
Hyperlipidemia and dyslipidemia make a substantial contribution to cardiovascular morbidity and mortality in people with diabetes mellitus.
Pharmacotherapy with statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and bempedoic acid has convincingly been shown to reduce the cardiovascular risk of people with diabetes.
The present article presents the treatment recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in people with diabetes according to current scientific evidence.
Conclusions In the Italian cohort of the MILOS study, BA, alone or in BA+EZE FDC, proved to be an effective therapeutic option for managing patients at CV risk, supporting its role in achieving guideline-recommended lipid-lowering goals in real-world clinical practice.
Giammanco A, Gambacurta R, Gouni-Berthold I, Jukema JW, Roeters van Lennep JE, Ray K, Koskinas K, Stulnig T, Vanassche T, Lamparter M, Wenz-Pöschl K, Chhabra R, De Muniategui Climente M, Pintó X, Parhofer KG, Averna M, a nome del Gruppo di Studio MILOS. · Giornale italiano di cardiologia (2006) (2026)
The overall mean age was 66.0 ± 10.7 years; heterozygous familial hypercholesterolemia was present in 11.1%, and 15.1% had diabetes.
A larger proportion of patients (57.7%) were in secondary prevention, and 82.4% were at high or very high CV risk.
Before starting BA or BA+EZE FDC, 33.1% of patients were not receiving lipid-lowering therapy.
More than 60% of patients achieved and sustained their LDL-C target levels.
Masuda D, Kajinami K, Sakayoshi N, Yokota D, Nagamine M, Morikawa-Isogai Y, Yamashita S. · Journal of atherosclerosis and thrombosis (2026)
Treatment-emergent adverse events (TEAEs) occurred in 83.8%, treatment-related TEAEs in 14.6%, serious TEAEs in 6.2%, and AEs leading to discontinuation in 4.6%.
Between baseline and Week 52, low-density lipoprotein-cholesterol (LDL-C) decreased by 21.6% (overall population) and 25.3% (newly enrolled group), as observed in both statin response subgroups.
LDL-C target levels based on risk category were achieved by 65.6% at Week 52 (overall population).
Moving beyond uniform targets toward etiologic and genetically informed lipid modulation may improve post-stroke outcomes and refine individualized stroke prevention.
Stefanou MI et al. · International journal of stroke : official journal of the International Stroke Society (2026)
In intracerebral hemorrhage (ICH), the optimal intensity and thresholds of lipid lowering remain uncertain, warranting individualized weighting of ischemic against hemorrhagic risk, particularly in patients with lobar ICH or suspected cerebral amyloid angiopathy (CAA).
In such cases, hydrophilic statins, ezetimibe, or PCSK9 inhibitors may represent reasonable options.
This review synthesizes current evidence and proposes a phenotype-guided, individualized framework for dyslipidemia management across stroke subtypes.
Humphrey R et al. · British journal of hospital medicine (London, England : 2005) (2026)
More recently, RNA-based therapies, oral small molecule inhibitors, and gene-editing strategies have emerged, which may offer even greater LDL-C reduction.
As evidence increasingly supports a "lower is better" approach, combining established and novel therapies offers opportunities to optimise ASCVD prevention.
This review summarises the evolving landscape of LDL-C-lowering therapies, highlighting their mechanisms, evidence base, and implications for clinical practice.
Antwi K et al. · British journal of hospital medicine (London, England : 2005) (2026)
While statins remain the foundation of lipid-lowering therapy, the treatment options have expanded and we discuss the role of ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, inclisiran, and bempedoic acid.
We also look ahead to gene-editing strategies and lipoprotein (a) lowering therapies currently in clinical trials.
By simplifying these recent advances, this review aims to provide hospital clinicians with a practical approach to identify high-risk patients, optimise their therapy and reduce cardiovascular disease burden.
19Beobachtungsstudien=6,025 · very large study2026
Results should be interpreted in the context of currently available cardiovascular outcomes evidence, pending dedicated outcomes and long-term safety data.
Matteucci A, Di Fusco SA, Bonanni M, Marino G, Fedele S, Nardi F, Colivicchi F. · Journal of clinical lipidology (2026)
The primary outcome was the mean percentage change in LDL-C from baseline vs placebo.
The secondary outcome was the mean percentage change in non-high-density lipoprotein cholesterol (non-HDL-C), treatment safety, including adverse events, serious adverse events, and cardiovascular composite endpoint.
Obicetrapib resulted in a pooled LDL-C reduction of -33.17% (95% CI, -36.21 to -30.13) vs placebo, whereas bempedoic acid produced a reduction of -18.02% (95% CI, -18.83 to -17.21).